OYC International, Inc.

Recombinant Human Soluble RANKL (sRANKL) Launched in USA

OYC International Inc. is pleased to announce the launch of recombinant human soluble RANKL (sRANKL) to support osteoporosis and bone metabolism research initiatives. Receptor activator of NF-kB ligand (RANKL), also designated TRANCE, OPGL and ODF, is a member of the TNF family that is expressed... - November 07, 2008